Hepatic Injury Caused by Acarbose
Authors: Raul J. Andrade
Journal: Annals of Internal Medicine (1996)

Letters15 May 1996Hepatic Injury Caused by AcarboseRaul J. Andrade, MD, M. Isabel Lucena, MD, and M. Rodriguez-Mendizabal, MDRaul J. Andrade, MDUniversity Hospital School of Medicine; 29071 Malaga, SpainSearch for more papers by this author, M. Isabel Lucena, MDUniversity Hospital School of Medicine; 29071 Malaga, SpainSearch for more papers by this author, and M. Rodriguez-Mendizabal, MDUniversity Hospital School of Medicine; 29071 Malaga, SpainSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-10-199605150-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Acarbose, a competitive inhibitor of α-glucosidases, delays absorption of carbohydrates in the gut, thereby decreasing postprandial glucose levels [1]. A recent clinical trial published in Annals supports the efficacy of acarbose in improving long-term glycemic control in patients with non–insulin-dependent diabetes mellitus [2]. We describe a patient who developed hepatic injury caused by acarbose treatment.A 65-year-old woman had received a diagnosis of non–insulin-dependent diabetes mellitus 7 years before presentation, for which glibenclamide was indicated. By mid-1993, acarbose (100 mg three times daily) was added to the treatment. Two months later, the patient presented with malaise and ...References1. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 1993; 46:1025-54. Google Scholar2. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al. The efficacy of acarbose in the treatment of patients with non–insulin-dependent diabetes. A multicenter controlled clinical trial. Ann Intern Med. 1994; 121:928-35. Google Scholar3. Report of an International Consensus Meeting. Criteria of drug-induced liver disorders. J Hepatol. 1990; 11:272-6. Google Scholar4. Kaplowitz N, Yee T, Simon FR, Stolz A. Drug-induced hepatotoxicity. Ann Intern Med. 1986; 104:826-39. Google Scholar Author, Article, and Disclosure InformationAffiliations: University Hospital School of Medicine; 29071 Malaga, Spain PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByHepatic and cardiovascular safety of acarbose among type 2 diabetes patients with end-stage renal disease: A nationwide population-based longitudinal studySpecificity of transaminase activities in the prediction of drug-induced hepatotoxicityAcarbose Use and Liver Injury in Diabetic Patients With Severe Renal Insufficiency and Hepatic Diseases: A Propensity Score-Matched Cohort StudyDrugs and ToxinsThe Inhibitory Effects of Yixing Black Tea Extracts on A-GlucosidaseAlpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysisRisk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patientsα-Glucosidase inhibitorsTissue Distribution and Identification of Radioactivity Components at Elimination Phase after Oral Administration of [ 14 C]CS-1036, an α -Amylase Inhibitor, to RatsHepatotoxicity of Cardiovascular and Antidiabetic DrugsHepatic injury due to drugs, herbal compounds, chemicals and toxinsEffect of Acarbose on Vascular Disease in Patients with Abnormal Glucose ToleranceThe Multifaceted Associations of Hepatobiliary Disease and DiabetesMechanisms and Outcomes of Drug- and Toxicant-Induced Liver Toxicity in DiabetesDrug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year PeriodHepatotoxicity Associated with Acarbose TherapyDrug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year PeriodA randomized controlled trial of acarbose in hepatic encephalopathyNarrative Review: Hepatobiliary Disease in Type 2 Diabetes MellitusKeith G. Tolman, MD, Vivian Fonseca, MD, Meng H. Tan, MD, and Anthony Dalpiaz, PharmDï¿½ï¿½-Glucosidase InhibitorsHepatotoxicity of the thiazolidinedionesThe Liver, Liver Disease, and Diabetes MellitusProspective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugsAcarbose-induced liver injury in an anti-hepatic C virus positive patientOral agents for the treatment of type 2 diabetes mellitus: Pharmacology, toxicity, and treatmentHepatitis aguda inducida por acarbosaUtilidad de los de registros de hepatotoxicidad por fármacosNONHYPOGLYCEMIC DRUG REACTIONS OF AGENTS USED TO TREAT DIABETESPathophysiology and Pharmacological Treatment of Insulin Resistance*Acarbose-induced generalised erythema multiformeAcarbose alone or in combination with ethanol potentiates the hepatotoxicity of carbon tetrachloride and acetaminophen in ratsAcarbose-Induced Acute HepatitisDIABETES AND THE HEPATOBILIARY SYSTEMInsulin, glucagon, and hypoglycemic drugsSafe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarboseAcarbose-induced acute severe hepatotoxicityAcarbose 15 May 1996Volume 124, Issue 10Page: 931KeywordsAlanine aminotransferaseBilirubinBiopsyDrugsLiverOral administrationResearch laboratoriesSerum glutamic oxaloacetic transaminaseType 2 diabetesUltrasound imaging Issue Published: 15 May 1996 CopyrightCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...